Further studies have shown that irisin can modulate immuno-inflammatory in experimentally induced RA in rats by inhibiting the expression of receptor-interacting protein kinase 1 (RIPK1) and mixed-lineage kinase domain-like protein (MLKL) expression, thereby ameliorating the pathogenesis of RA (98). Here, MLKL is linked to rheumatoid arthritis.